As of 2024-11-04, the EV/EBITDA ratio of Lexicon Pharmaceuticals Inc (LXRX) is -2.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LXRX's latest enterprise value is 504.90 mil USD. LXRX's TTM EBITDA according to its financial statements is -185.06 mil USD. Dividing these 2 quantities gives us the above LXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 9.7x - 17.3x | 14.4x |
Forward P/E multiples | 15.2x - 17.7x | 17.6x |
Fair Price | (7.96) - (9.02) | (8.37) |
Upside | -752.3% - -839.6% | -785.9% |
Date | EV/EBITDA |
2024-10-29 | -4.31 |
2024-10-28 | -3.98 |
2024-10-25 | -3.86 |
2024-10-24 | -3.94 |
2024-10-23 | -3.98 |
2024-10-22 | -4.13 |
2024-10-21 | -4.15 |
2024-10-18 | -4.41 |
2024-10-17 | -4.27 |
2024-10-16 | -4.08 |
2024-10-15 | -3.84 |
2024-10-14 | -3.84 |
2024-10-11 | -3.74 |
2024-10-10 | -3.65 |
2024-10-09 | -3.53 |
2024-10-08 | -3.63 |
2024-10-07 | -3.63 |
2024-10-04 | -3.65 |
2024-10-03 | -3.49 |
2024-10-02 | -3.49 |
2024-10-01 | -3.43 |
2024-09-30 | -3.41 |
2024-09-27 | -3.47 |
2024-09-26 | -3.35 |
2024-09-25 | -3.29 |
2024-09-24 | -3.41 |
2024-09-23 | -3.43 |
2024-09-20 | -3.59 |
2024-09-19 | -3.65 |
2024-09-18 | -3.55 |
2024-09-17 | -3.51 |
2024-09-16 | -3.53 |
2024-09-13 | -3.67 |
2024-09-12 | -3.61 |
2024-09-11 | -3.65 |
2024-09-10 | -3.61 |
2024-09-09 | -3.61 |
2024-09-06 | -3.49 |
2024-09-05 | -3.51 |
2024-09-04 | -3.53 |
2024-09-03 | -3.49 |
2024-08-30 | -3.72 |
2024-08-29 | -3.86 |
2024-08-28 | -3.70 |
2024-08-27 | -3.70 |
2024-08-26 | -3.80 |
2024-08-23 | -3.92 |
2024-08-22 | -3.92 |
2024-08-21 | -4.08 |
2024-08-20 | -3.63 |